About Xencor (NASDAQ:XNCR)
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:XNCR
- CUSIP: N/A
- Web: www.xencor.com
Capitalization:- Market Cap: $961.04 million
- Outstanding Shares: 46,926,000
Average Prices:- 50 Day Moving Avg: $22.80
- 200 Day Moving Avg: $22.43
- 52 Week Range: $18.45 - $29.38
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.91
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $31.94 million
- Price / Sales: 30.09
- Book Value: $6.43 per share
- Price / Book: 3.19
Profitability:- EBITDA: ($40,410,000.00)
- Net Margins: -121.04%
- Return on Equity: -13.79%
- Return on Assets: -9.76%
Debt:- Current Ratio: 1.96%
- Quick Ratio: 1.96%
Misc:- Average Volume: 169,855 shs.
- Beta: 2.16
- Short Ratio: 15.68
Frequently Asked Questions for Xencor (NASDAQ:XNCR)
What is Xencor's stock symbol?
Xencor trades on the NASDAQ under the ticker symbol "XNCR."
How were Xencor's earnings last quarter?
Xencor, Inc. (NASDAQ:XNCR) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.10. The firm earned $13.34 million during the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. View Xencor's Earnings History.
Where is Xencor's stock going? Where will Xencor's stock price be in 2017?
5 analysts have issued 12-month price targets for Xencor's shares. Their predictions range from $21.00 to $36.00. On average, they expect Xencor's stock price to reach $28.00 in the next year. View Analyst Ratings for Xencor.
What are analysts saying about Xencor stock?
Here are some recent quotes from research analysts about Xencor stock:
- 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (8/11/2017)
- 2. Instinet analysts commented, "We are initiating on XNCR with a Neutral rating and a $21 target price. We recommend stepping to the sidelines in 2017, as we anticipate that XNCR shares will trade flat relative to the biotechnology index over the next 12 months. We note that several near-term catalysts are likely already 'baked in' the current valuation, particularly for the '5871 IgG4- RD program. We believe that a key catalyst'meaningful data for XNCR's bispecific assets'is likely to lead to upside, but that it will occur beyond our 12-month horizon." (3/1/2017)
Who are some of Xencor's key competitors?
Some companies that are related to Xencor include Array BioPharma (ARRY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), NovoCure Limited (NVCR), Radius Health (RDUS), Acceleron Pharma (XLRN), AnaptysBio (ANAB), Clinigen Group PLC (CLIN), Five Prime Therapeutics (FPRX), Acorda Therapeutics (ACOR), Ascendis Pharma A/S (ASND), Dermira (DERM), Lexicon Pharmaceuticals (LXRX), MyoKardia (MYOK), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), NeuroDerm (NDRM) and Athenex (ATNX).
Who are Xencor's key executives?
Xencor's management team includes the folowing people:
- Bassil I. Dahiyat Ph.D., President, Chief Executive Officer, Founder, Director
- John R. Desjarlais Ph.D., Senior Vice President, Research and Chief Scientific Officer
- Paul Foster M.D., Senior Vice President, Chief Medical Officer
- John J. Kuch, Vice President - Finance
- Edgardo Baracchini Jr. Ph.D., Chief Business Officer
- A. Bruce Montgomery M.D., Lead Independent Director
- Kevin C. Gorman Ph.D., Independent Director
- Kurt A. Gustafson, Independent Director
- Yujiro S. Hata, Independent Director
Who owns Xencor stock?
Xencor's stock is owned by many different of institutional and retail investors. Top institutional investors include Nationwide Fund Advisors (0.13%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.
Who bought Xencor stock? Who is buying Xencor stock?
How do I buy Xencor stock?
Shares of Xencor can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xencor's stock price today?
One share of Xencor stock can currently be purchased for approximately $20.48.
MarketBeat Community Rating for Xencor (NASDAQ XNCR)MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Xencor (NASDAQ:XNCR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.60) |
| Consensus Price Target: | $28.00 (36.72% upside) |
Consensus Price Target History for Xencor (NASDAQ:XNCR)
Analysts' Ratings History for Xencor (NASDAQ:XNCR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/23/2017 | Canaccord Genuity | Set Price Target | Buy | $36.00 | N/A |  |
| 6/16/2017 | Wedbush | Reiterated Rating | Outperform | $29.00 | Low | |
| 3/1/2017 | Instinet | Initiated Coverage | Neutral -> Neutral | $21.00 | N/A | |
| 3/1/2017 | Nomura | Initiated Coverage | Neutral | | N/A | |
| 11/3/2016 | Leerink Swann | Reiterated Rating | Buy | $26.00 | N/A | |
| 10/4/2016 | Piper Jaffray Companies | Initiated Coverage | Overweight | $35.00 | N/A | |
| 5/2/2016 | Oppenheimer Holdings, Inc. | Reiterated Rating | Buy | | N/A | |
| 12/22/2015 | FBR & Co | Reiterated Rating | Buy | $20.00 | N/A | |
(Data available from 10/23/2015 forward)
Earnings History for Xencor (NASDAQ:XNCR)Earnings History by Quarter for Xencor (NASDAQ XNCR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2017 | Q2 2017 | ($0.25) | ($0.15) | $8.15 million | $13.34 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.25) | ($0.31) | $8.15 million | $4.34 million | View | Listen | |
| 8/2/2016 | Q216 | ($0.18) | $1.13 | $7.43 million | $66.00 million | View | N/A | |
| 5/2/2016 | Q116 | ($0.27) | ($0.16) | $3.50 million | $7.30 million | View | N/A | |
| 3/7/2016 | Q415 | ($0.30) | $0.19 | $2.50 million | $21.80 million | View | N/A | |
| 11/3/2015 | Q315 | ($0.17) | ($0.25) | $3.57 million | $3.50 million | View | N/A | |
| 8/4/2015 | Q215 | ($0.18) | ($0.22) | $1.90 million | $1.01 million | View | N/A | |
| 5/4/2015 | Q115 | ($0.17) | ($0.19) | $1.90 million | $1.49 million | View | Listen | |
| 2/19/2015 | | ($0.22) | ($0.04) | $1.33 million | $5.66 million | View | N/A | |
| 11/10/2014 | Q3 14 | ($0.19) | ($0.20) | $1.50 million | $0.85 million | View | N/A | |
| 7/31/2014 | | ($0.19) | ($0.16) | | $0.82 million | View | N/A | |
| 5/14/2014 | Q1 14 | ($0.16) | ($0.12) | $1.71 million | $2.20 million | View | N/A | |
| 3/19/2014 | Q413 | ($0.14) | ($0.24) | $1.71 million | $1.70 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Xencor (NASDAQ:XNCR)2017 EPS Consensus Estimate: ($0.95)
2018 EPS Consensus Estimate: ($1.71)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.22) | ($0.17) | ($0.20) |
| Q2 2017 | 2 | ($0.29) | ($0.19) | ($0.24) |
| Q3 2017 | 2 | ($0.32) | ($0.23) | ($0.28) |
| Q4 2017 | 2 | ($0.24) | ($0.24) | ($0.24) |
| Q1 2018 | 1 | ($0.39) | ($0.39) | ($0.39) |
| Q2 2018 | 1 | ($0.42) | ($0.42) | ($0.42) |
| Q3 2018 | 1 | ($0.44) | ($0.44) | ($0.44) |
| Q4 2018 | 1 | ($0.46) | ($0.46) | ($0.46) |
(Data provided by Zacks Investment Research)
Dividend History for Xencor (NASDAQ:XNCR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Xencor (NASDAQ:XNCR)Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 76.92%
Insider Trades by Quarter for Xencor (NASDAQ:XNCR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/22/2017 | John S Stafford III | Major Shareholder | Buy | 41,016 | $19.69 | $807,605.04 | |
| 8/18/2017 | John S Stafford III | Major Shareholder | Buy | 43,500 | $19.93 | $866,955.00 | |
| 8/17/2017 | John S Stafford III | Major Shareholder | Buy | 79,035 | $20.47 | $1,617,846.45 | |
| 8/16/2017 | John S Stafford III | Major Shareholder | Buy | 25,000 | $20.96 | $524,000.00 | |
| 8/11/2017 | John S Stafford III | Major Shareholder | Buy | 27,000 | $21.13 | $570,510.00 | |
| 6/28/2017 | John S Stafford III | Major Shareholder | Buy | 6,000 | $19.94 | $119,640.00 | |
| 6/16/2017 | John S Stafford III | Major Shareholder | Buy | 1,500 | $19.67 | $29,505.00 | |
| 6/14/2017 | Bruce L A Carter | Director | Sell | 20,000 | $20.61 | $412,200.00 | |
| 6/2/2017 | Bruce L A Carter | Director | Sell | 2,366 | $22.00 | $52,052.00 | |
| 5/26/2017 | Bruce L A Carter | Director | Sell | 12,400 | $22.19 | $275,156.00 | |
| 5/2/2017 | Edgardo Baracchini Jr | Insider | Sell | 10,568 | $26.01 | $274,873.68 | |
| 4/27/2017 | Edgardo Baracchini Jr | Insider | Sell | 904 | $26.04 | $23,540.16 | |
| 3/16/2017 | John J. Kuch | VP | Sell | 15,000 | $24.42 | $366,300.00 | |
| 3/8/2017 | Edgardo Baracchini Jr | Insider | Sell | 1,821 | $25.00 | $45,525.00 | |
| 12/6/2016 | John S Stafford III | Major Shareholder | Sell | 63,061 | $27.71 | $1,747,420.31 | |
| 9/28/2016 | Edgardo Baracchini Jr | Insider | Sell | 10,000 | $25.35 | $253,500.00 | |
| 9/27/2016 | John S Stafford III | Major Shareholder | Sell | 40,000 | $25.72 | $1,028,800.00 | |
| 9/2/2016 | Edgardo Baracchini Jr | Insider | Sell | 10,000 | $21.06 | $210,600.00 | |
| 8/30/2016 | Bassil I Dahiyat | Insider | Sell | 40,000 | $21.80 | $872,000.00 | |
| 8/26/2016 | John S Stafford III | Major Shareholder | Sell | 24,351 | $21.48 | $523,059.48 | |
| 8/24/2016 | John J Kuch | VP | Sell | 25,000 | $21.95 | $548,750.00 | |
| 8/23/2016 | John R Desjarlais | VP | Sell | 16,294 | $21.73 | $354,068.62 | |
| 8/23/2016 | John S Stafford III | Major Shareholder | Sell | 96,828 | $21.73 | $2,104,072.44 | |
| 8/16/2016 | Bassil I Dahiyat | Insider | Sell | 45,886 | $22.06 | $1,012,245.16 | |
| 8/15/2016 | Bruce L A Carter | Director | Sell | 3,400 | $22.67 | $77,078.00 | |
| 8/15/2016 | John S Stafford III | Major Shareholder | Sell | 10,000 | $23.06 | $230,600.00 | |
| 8/11/2016 | John S Stafford III | Major Shareholder | Sell | 30,500 | $21.87 | $667,035.00 | |
| 8/10/2016 | Edgardo Baracchini Jr | Insider | Sell | 2,500 | $21.83 | $54,575.00 | |
| 8/3/2016 | Edgardo Baracchini, Jr. | Insider | Sell | 4,528 | $20.00 | $90,560.00 | |
| 8/3/2016 | John R. Desjarlais | VP | Sell | 5,905 | $20.00 | $118,100.00 | |
| 7/11/2016 | Edgardo Baracchini Jr | Insider | Sell | 1,250 | $18.13 | $22,662.50 | |
| 6/28/2016 | Edgardo Baracchini Jr | Insider | Sell | 1,250 | $15.10 | $18,875.00 | |
| 5/24/2016 | Bassil I Dahiyat | CEO | Sell | 45,886 | $13.00 | $596,518.00 | |
| 4/7/2016 | Edgardo Baracchini Jr | Insider | Sell | 3,750 | $15.00 | $56,250.00 | |
| 3/17/2016 | Bassil I Dahiyat | CEO | Sell | 45,886 | $11.02 | $505,663.72 | |
| 3/3/2016 | John R Desjarlais | VP | Sell | 14,260 | $12.01 | $171,262.60 | |
| 2/1/2016 | John S Stafford III | Major Shareholder | Sell | 25 | $10.79 | $269.75 | |
| 1/29/2016 | John S Stafford III | Major Shareholder | Buy | 25 | $10.83 | $270.75 | |
| 1/4/2016 | John R. Desjarlais | VP | Sell | 1,100 | $14.13 | $15,543.00 | |
| 12/17/2015 | John J Kuch | VP | Sell | 4,781 | $14.89 | $71,189.09 | |
| 12/16/2015 | Paul A. Foster | insider | Sell | 6,025 | $15.01 | $90,435.25 | |
| 12/3/2015 | John S. Stafford III | Director | Sell | 30,000 | $15.13 | $453,900.00 | |
| 11/25/2015 | Edgardo Baracchini, Jr. | insider | Sell | 2,500 | $15.00 | $37,500.00 | |
| 9/3/2015 | John S Stafford III | Director | Sell | 10,000 | $17.22 | $172,200.00 | |
| 9/1/2015 | Edgardo Baracchini, Jr. | insider | Sell | 1,250 | $16.49 | $20,612.50 | |
| 7/6/2015 | John S Stafford III | Director | Sell | 10,000 | $22.29 | $222,900.00 | |
| 7/1/2015 | Edgardo Baracchini Jr | Insider | Sell | 2,500 | $22.24 | $55,600.00 | |
| 6/16/2015 | John S Stafford III | Director | Sell | 20,000 | $20.35 | $407,000.00 | |
| 6/15/2015 | Bruce L A Carter | Director | Sell | 10,000 | $19.21 | $192,100.00 | |
| 6/15/2015 | Edgardo Baracchini Jr | Insider | Sell | 1,277 | $19.85 | $25,348.45 | |
| 6/12/2015 | John J Kuch | VP | Sell | 8,756 | $19.35 | $169,428.60 | |
| 6/12/2015 | John S Stafford III | Director | Sell | 250,000 | $19.00 | $4,750,000.00 | |
| 6/3/2015 | John S Stafford III | Director | Sell | 10,000 | $18.76 | $187,600.00 | |
| 6/1/2015 | Edgardo Baracchini Jr | Insider | Sell | 1,250 | $18.14 | $22,675.00 | |
| 5/26/2015 | John S Stafford III | Director | Sell | 10,000 | $17.01 | $170,100.00 | |
| 5/15/2015 | Edgardo Baracchini Jr | Insider | Sell | 1,604 | $15.00 | $24,060.00 | |
| 8/11/2014 | John S Stafford III | Director | Sell | 124,000 | $9.37 | $1,161,880.00 | |
| 12/6/2013 | John S Stafford III | Director | Buy | 275,000 | $5.50 | $1,512,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Xencor (NASDAQ:XNCR)
Latest Headlines for Xencor (NASDAQ:XNCR)
| Source: |
|
Loading headlines, please wait.
Xencor (XNCR) Chart for Monday, October, 23, 2017
